

The Impact of Metabolic Syndrome on Increased Risk of Thyroid Nodules and Size

Health Services Research and
Managerial Epidemiology
Volume 5: 1-6
© The Author(s) 2018
Reprints and permission:
sagepub.com/journalsPermissions.nav
DOI: 10.1177/2333392818775517
journals.sagepub.com/home/hme



Abdulbari Bener^{1,2,3}, Yaşar Özdenkaya³, Cem Cahit Barışık⁴,
and Mustafa Öztürk⁵

Abstract

Aim: The present research aimed to determine the relation between metabolic syndrome (MetS) and thyroid volume and nodule prevalence among Turkish population patients.

Methods: This retrospective cohort study was carried on 850 patients between the ages of 20 and 65 who visited the diabetic, endocrinology, and general surgery outpatient clinics in the Mega Medipol and Medipol Hospital between January 2014 and December 2017. This study included sociodemographic information, body mass index (BMI), diabetes mellitus (DM), systolic (SBP) and diastolic (DBP) blood pressures, and clinical biochemistry results such as serum triglyceride, total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein (LDL) cholesterol, hemoglobin A1c (HbA1c), fasting blood glucose levels, thyroid-stimulating hormone (TSH), T3, T4, and other MetS parameters. Thyroid fine needle aspiration biopsy was suggested to patients whose thyroid nodules were greater than 1.00 cm. The definition and diagnostic of MetS used as proposed by the National Cholesterol Education Program—Third Adult Treatment Panel.

Results: There were statistically significant differences between patients with thyroid nodules and those without regarding age, gender, BMI, physical activity, cigarette smoking, shisha smoking, family history of diabetes, hypertension, and thyroid. Meanwhile, statistically significant differences were found between with and without MetS for calcium ($P = .028$), magnesium ($P < .001$), potassium ($P < .001$), fasting blood glucose ($P = .047$), HbA1c ($P < .001$), HDL ($P < .001$), LDL ($P < .001$), albumin ($P = .008$), bilirubin ($P = .002$), triglyceride ($P = .011$), SBP ($P = .001$) and DBP ($P = .011$), TSH ($P = .005$), T3 ($P < .001$), and T4 ($P < .001$). Furthermore, there were statistically significant differences between participants with and without thyroid nodules for calcium ($P < .001$), magnesium ($P < .001$), potassium ($P < .001$), fasting blood glucose ($P = .010$), HbA1c ($P = .019$), HDL ($P < .001$), LDL ($P = .012$), albumin ($P = .002$), bilirubin ($P < .001$), triglyceride ($P < .001$), SBP ($P < .001$) and DBP ($P = .004$), TSH ($P = .015$), T3 ($P < .001$), and T4 ($P < .001$). Multivariate stepwise logistic regression analysis used for independent predictors for the presence of thyroid nodules which TSH ($P < .001$), family history of thyroid and DM ($P < .001$), age in years ($P = .025$), DBP and SBP ($P < .001$), BMI ($P = .014$), HDL-C ($P = .034$), and waist circumference (in cm; $P = .044$) were considered at higher risk as a predictors of thyroid with patients with MetS.

Conclusion: The results of the current study confirm a strong positive association between MetS and thyroid nodules risk among patients with MetS. This study suggest that the patients with MetS can be considered as a marker to have moderately increased risk of future thyroid nodules and cancer. Meanwhile, MetS, obesity, and hyperglycemia could be a qualifiable and modifiable risk

¹ Department of Biostatistics and Medical Informatics, Cerrahpaşa Faculty of Medicine, Istanbul University, Istanbul, Turkey

² Department of Evidence for Population Health Unit, School of Epidemiology and Health Sciences, The University of Manchester, Manchester, United Kingdom

³ Department of Surgery, Medipol School of Medicine, Istanbul Medipol University, Istanbul, Turkey

⁴ Department of Pathology, Medipol School of Medicine, Istanbul Medipol University, Istanbul, Turkey

⁵ Department of Endocrinology, Medipol International School of Medicine, Istanbul Medipol University, Istanbul, Turkey

Submitted April 06, 2018. Revised April 07, 2018. Accepted April 07, 2018.

Corresponding Author:

Abdulbari Bener, Department of Biostatistics and Medical Informatics, Cerrahpaşa Faculty of Medicine, Istanbul University and Istanbul Medipol University, International School of Medicine, 34098 Cerrahpaşa, Istanbul, Turkey.

Emails: abdulbari.bener@istanbul.edu.tr; abener99@yahoo.com



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<http://www.creativecommons.org/licenses/by-nc/4.0/>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).

factor for thyroid nodules. The regularly glycemic control may be the most important treatment for the reduction of incidence or the prevention of thyroid.

Keywords

epidemiology, T2DM, metabolic syndrome, thyroid, prevention

Introduction

Metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) are the main threats to the 21st century and impress the health and economic status of most countries.¹ Metabolic syndrome leads to an increase in the risk of cardiovascular disease²⁻³ and thyroid⁴⁻⁶ in long term. They are the primary reason of mortality and morbidity in most high-income and developing countries.³ Lifestyle factors, sleep duration, physical activity, regular exercise, and healthy-balanced diet are essential components in the prevention of MetS.³

Overall, in the last 3 decades, the incidence and prevalence of thyroid cancer, in other words papillary histotype, has indicated a stable rise around the world.⁵⁻⁸ Metabolic syndrome is a clustering of medical conditions that reflects overweight, obesity, sedentary lifestyles, stress, hypertension, hyperglycemia, and dyslipidemia,^{3,8,9} which they are not independent of one another and that they may share underlying causes and mechanisms.⁸ In several studies, MetS is considered as a risk factor for cardiovascular disease and thyroid.¹⁰⁻¹³ Positive associations between MetS and thyroid nodules have been reported by several authors.^{10,13} The present research aimed to determine the relation between MetS and thyroid volume and nodule prevalence among Turkish population patients.

Participants and Methods

This retrospective study was performed on participants between the ages of 20 and 60 who visited the diabetes, endocrinology, thyroid surgery, and outpatient clinics in the Mega Medipol International School of Medicine Hospital and Medipol Hospital from January 2014 to December 2017. The current sample size was based on the detected as 850 case series registered with diagnosed MetS and thyroid nodule to be included to meet specific objectives. The Institutional Review Board (IRB) ethical approval for the present study was taken from the Medipol International School of Medicine, Istanbul Medipol University, and patients gave informed written consent before starting.

Laboratory Measurements

Patients were considered to have DM if they have a history of DM and were currently taking any oral medications for diabetes. According to the World Health Organization (WHO) and International Diabetes Federation (IDF), DM is defined when fasting venous blood glucose concentration is equal or higher than 7.0 mmol/L and/or postprandial blood glucose concentration is higher than 11.1 mmol/L.^{1,9} A glucometer was used to

measure fasting blood glucose of all patients. Oral glucose tolerance test was carried out only if blood sugar was less than 7 mmol/L. The inclusion criteria comprised of diagnosis of T2DM in conformity with international standards by WHO and IDF.^{1,9}

The definition and diagnostic of MetS used as proposed by the National Cholesterol Education Program–Third Adult Treatment Panel guidelines^{1,9,14}: (1) a participant has the MetS of waist circumference higher than 94 cm in men and 80 cm in women; (2) level of fasting glucose level has to be higher than 100 mg/dL (5.6 mmol/L) or a participant must have been previously diagnosed with impaired fasting glucose; (3) level of blood pressure has to be higher than 130/85 mm Hg or a participant was cured for hypertension; (4) level of triglyceride must have been measured to be higher than 150 mg/dL (1.7 mmol/L); (5) level of high-density lipoprotein cholesterol (HDL-C) must be less than 40 mg/dL (1.03 mmol/L) in men and 50 mg/dL (1.29 mmol/L) in women or participant was cured for low HDL.

Thyroid Evaluation

A thyroid nodule is a lump that occurs from the abnormal growth of thyroid cells, located at the base of the neck, and produces the hormones thyroxine and triiodothyronine.¹⁵ A 10-MHz linear probe (Logiq 5 Pro, GE Medical Systems, Wisconsin) was used by same physician (C.C.B.) for thyroid ultrasonography. Thyroid fine needle aspiration biopsy was suggested to patients whose thyroid nodules were higher than 1.00 cm.

Questionnaire, Physical Examination, and Measurements

This study included several parameters such as sociodemographic characteristics, lifestyle habits, and biochemical test results. Patients were classified as physically active if they walked or cycled for more than 30 minutes per day.

The data were analyzed using the Statistical Package for the Social Sciences (IBM SPSS Statistics for Windows, version 22.0; IBM Corp, Armonk, New York). The significance of differences between mean values of 2 continuous variables was determined by Student *t* test for normal distribution data and by Mann-Whitney *U* test for not normal distribution data. Chi-square test tested the differences in proportions of categorical variables between 2 or more groups. Multivariate logistic regression analysis using the forward inclusion and backward deletion method was used to assess the relationship between dependent and independent variables and to adjust for potential confounders and orders the importance of risk factors

Table 1. Comparison of Sociodemographic and Clinical Characteristics of the Metabolic Variables and Presence of Thyroid Nodules in Participants.^a

Variables	Thyroid		Odds Ratio (95% CI)	P Value
	With Thyroid Nodule, n = 212	Without Thyroid Nodule, n = 638		
Age groups (in years)				
>30	26 (12.3)	54 (8.5)	1	
30-39	41 (9.3)	96 (15.0)	0.89 (0.48-1.60)	.692
40-49	46 (21.7)	154 (24.1)	0.89 (0.48-1.60)	.101
50-59	54 (25.9)	141 (22.1)	0.62 (0.35-1.09)	.425
60 and above	45 (21.2)	193 (30.3)	0.89 (0.53-1.47)	.012
Gender				
Male	91 (42.9)	221 (34.6)	1.41 (1.03-1.94)	.030
Female	121 (57.1)	417 (65.4)	1	
BMI (kg/m ²)				
Normal (<25 kg/m ²)	51 (24.1)	194 (30.4)	1	
Overweight (29-30 kg/m ²)	92 (43.4)	285 (44.7)	1.22 (0.83-1.80)	.299
Obese (>30 kg/m ²)	69 (32.5)	101 (24.9)	1.66 (1.08-2.50)	.018
Physical activity				
Yes	43 (20.3)	179 (28.1)	1	
No	169 (79.7)	459 (71.9)	0.65 (0.55-0.95)	.026
Smoking status				
Never	164 (77.4)	538 (84.3)	1	
Current smoker	36 (17.0)	66 (10.3)	1.78 (1.15-2.78)	.009
Past smoker	12 (5.6)	34 (5.3)	1.15 (0.58-2.28)	.673
Shisha smoking status				
Yes	37 (17.9)	74 (11.6)	1.61 (1.04-2.47)	.028
No	175 (82.5)	564 (88.4)	1	
Family history of DM				
Yes	32 (15.1)	64 (10.0)	1.70 (1.01-2.51)	.044
No	180 (84.9)	574 (90.0)	1	
Family history of hypertension				
Yes	57 (26.9)	115 (18.0)	1.67 (1.16-2.41)	.005
No	155 (73.1)	523 (82.0)	1	
Family history of thyroid				
Yes	27 (12.7)	24 (3.8)	3.73 (2.10-6.62)	.001
No	185 (87.3)	614 (96.2)	1	

Abbreviations: BMI, body mass index; CI, confidence interval; DM, diabetes mellitus.

^aN = 850.

(determinants) to predict the factors for the presence of thyroid nodules. The cutoff value for determining significance was chosen as 0.05.

Results

Table 1 presents the comparison of sociodemographic and clinical characteristics of the metabolic variables and presence of thyroid nodules in participants. There were statistically significant differences between patients with and without thyroid nodules regarding age, gender, body mass index (BMI), physical activity, cigarette smoking, shisha smoking, family history of diabetes, hypertension, and thyroid.

Table 2 shows the clinical biochemistry baseline value among MetS participants and presence of thyroid nodules in participants with and without metabolic syndrome. Statistically significant differences were found between with and without MetS for calcium ($P = .028$), magnesium ($P < .001$), potassium

($P < .001$), fasting blood glucose ($P = .047$), hemoglobin A1c (HbA1c; $P < .001$), HDL ($P < .001$), low-density lipoprotein (LDL) ($P < .001$), albumin ($P = .008$), bilirubin ($P = .002$), triglyceride ($P = .011$), systolic blood pressure (SBP; $P = .001$) and diastolic blood pressure (DBP; $P = .011$), thyroid-stimulating hormone (TSH; $P = .005$), T3 ($P < .001$), and T4 ($P < .001$).

Table 3 presents the clinical biochemistry baseline value among MetS participants with thyroid and without thyroid nodules. There were statistically significant differences between participants with and without thyroid nodules for calcium ($P < .001$), magnesium ($P < .001$), potassium ($P < .001$), fasting blood glucose ($P = .010$), HbA1c ($P = .019$), HDL ($P < .001$), LDL ($P = .012$), albumin ($P = .002$), bilirubin ($P < .001$), triglyceride ($P < .001$), SBP ($P < .001$) and DBP ($P = .004$), TSH ($P = .015$), T3 ($P < .001$), and T4 ($P < .001$).

Table 4 indicates multivariate stepwise logistic regression analysis of independent predictors for the presence of thyroid

Table 2. Clinical Biochemistry Baseline Value Among Metabolic Variables Participants and Presence of Thyroid Nodules in Participants.^{a,b}

Variables	With Metabolic Syndrome, n = 284, Mean (SD)	Without Metabolic Syndrome, n = 576, Mean (SD)	P Value
Hemoglobin (g/dL)	12.88 (2.38)	12.95 (2.26)	.285
Magnesium (mmol/L)	0.76 (0.08)	0.90 (0.09)	<.001
Potassium (mmol/L)	3.30 (0.41)	3.51 (0.54)	<.001
Calcium (mmol/L)	1.66 (0.61)	1.78 (0.68)	.028
Phosphorous (mmol/L)	1.42 (0.30)	1.56 (0.26)	.123
Creatinine (mmol/L)	69.61 (14.43)	65.01 (18.72)	.007
Fasting blood glucose (mmol/L)	6.68 (1.35)	6.93 (1.31)	.047
HbA1c	6.54 (1.47)	6.02 (1.32)	<.001
Cholesterol (mmol/L)	4.38 (0.91)	4.35 (0.75)	.589
HDL (mmol/L)	1.21 (0.39)	1.08 (0.41)	<.001
LDL (mmol/L)	1.97 (0.92)	1.72 (0.69)	<.001
Albumin (mmol/L)	40.09 (4.34)	41.28 (6.44)	.008
Bilirubin (mmol/L)	6.62 (2.83)	7.18 (2.31)	.002
Triglyceride (mmol/L)	1.65 (0.63)	1.53 (0.68)	.011
Uric acid (mmol/L)	270.5 (68.03)	274.9 (68.5)	.349
Systolic blood pressure (mm Hg)	126.24 (11.76)	122.80 (15.02)	.001
Diastolic blood pressure (mm Hg)	77.48 (75)	75.85 (9.42)	.011
Thyroid-stimulating hormone, TSH	2.83 (1.01)	2.62 (1.03)	.005
T3	2.14 (1.00)	1.67 (1.11)	<.001
T4	1.40 (0.89)	1.11 (0.58)	<.001

Abbreviations: HDL, high-density lipoprotein; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein.

^aN = 850.

^bThyroid-stimulating hormone (reference range, 0.35-4.0 mIU/L), free triiodothyronine (FT3; reference range, 1.71-4.71 pg/mL), and free thyroxine (FT4; reference range, 0.8-1.9 ng/dL).

Table 3. Clinical Biochemistry Baseline Value Among Metabolic Syndrome Participants With Thyroid and Without Thyroid Nodules.^a

Variables	With Thyroid Nodule, n = 212, Mean (SD)	Without Thyroid Nodule, n = 638, Mean (SD)	P Value
Hemoglobin (g/dL)	12.82 (2.23)	12.98 (2.40)	.278
Magnesium (mmol/L)	0.78 (0.08)	0.91 (0.09)	<.001
Potassium (mmol/L)	3.20 (0.31)	3.55 (0.56)	<.001
Calcium (mmol/L)	1.55 (0.45)	1.89 (0.70)	<.001
Phosphorous (mmol/L)	1.39 (0.32)	1.58 (0.39)	<.001
Creatinine (mmol/L)	70.61 (14.50)	66.20 (14.00)	.997
Fasting blood glucose (mmol/L)	6.77 (1.40)	6.33 (1.31)	.010
HbA1c	6.80 (1.45)	6.29 (1.43)	.019
Cholesterol (mmol/L)	4.53 (1.02)	4.30 (0.74)	.002
HDL (mmol/L)	1.28 (0.40)	1.06 (0.32)	<.001
LDL (mmol/L)	1.71 (0.62)	1.53 (1.00)	.012
Albumin (mmol/L)	41.2 (5.65)	38.33 (7.50)	.002
Bilirubin (mmol/L)	6.21 (2.46)	7.65 (2.58)	<.001
Triglyceride (mmol/L)	1.74 (0.54)	1.55 (0.71)	<.011
Uric acid (mmol/L)	274.3 (68.90)	271.0 (77.8)	.616
Systolic blood pressure (mm Hg)	128.8 (11.0)	123.6 (14.9)	<.001
Diastolic blood pressure (mm Hg)	78.4 (75)	75.9 (8.9)	.004
Thyroid-stimulating hormone, TSH	2.94 (0.84)	2.74 (1.01)	.015
T3	2.24 (0.94)	1.81 (1.15)	<.001
T4	1.52 (1.05)	1.12 (0.53)	<.001

Abbreviations: HDL, high-density lipoprotein; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein.

^aN = 850.

nodules. Thyroid-stimulating hormone (mIU/L; $P < .001$), family history of thyroid and DM ($P < .001$), age (in years; $P = .025$), DBP (mm Hg; $P < .001$), SBP (mm Hg; $P < .001$), BMI

($P = .014$), HDL-C ($P = .034$), and waist circumference (cm; $P = .044$) were considered at higher risk as predictors of thyroid for patients with MetS.

Table 4. Multivariate Stepwise Logistic Regression Analysis of Independent Predictors for the Presence of Thyroid Nodules.

Variables	Adjusted Odds Ratio (95% CI)	P Value
TSH, mIU/L	2.71 (1.63-4.39)	<.001
Family history of thyroid	2.98 (1.89-5.14)	<.001
Family history of DM	2.85 (1.77-4.96)	<.001
Diastolic blood pressure, mm Hg	2.07 (1.9-2.25)	.010
Systolic blood pressure, mm Hg	1.56 (1.11-2.15)	.012
BMI (kg/m ²)	3.13 (2.52-4.14)	.014
Age, in years	1.24 (1.12-2.31)	.025
HDL-C (mmol/L)	1.84 (1.55-2.18)	.034
Waist circumference, cm	1.98 (1.40-3.06)	.044

Abbreviations: BMI, body mass index; CI, confidence interval; DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; TSH, thyroid-stimulating hormone.

Discussion

This study determined the relationship between the presence of thyroid nodules and the components of MetS in healthy Turkish population with no evidence of iodine insufficiency. Although Turkey have moderately iodine-deficient area,¹⁶ the present study demonstrates that people with MetS had a higher prevalence of thyroid nodules. The current results revealed strong correlation between thyroid nodules and MetS elements, which may have important implications for the diagnosis and treatment of thyroid-related diseases, those results are consistent with the Korean study⁴ and pervious reported study in Turkey.¹⁶ Furthermore, MetS is usually recognized as a complication and risk for thyroid. Therefore, effective control of MetS is essential to reduce the incidence of thyroid in the middle age-group and may affect the quality of life. The elements of MetS lead to increase thyroid volume and nodule. These are consistent with the results of Ayturk et al¹² and Korean study⁴ that pointed out the insulin level as a predictor of thyroid volume increase. Further, the participants with MetS also had a higher prevalence of thyroid nodules larger than 1 cm, consistent with a previous study showing a positive association between insulin resistance and thyroid nodule size.^{4,10}

Furthermore, several studies reported that thyroid volume is related to a variety of risk factors such as iodine deficiency and supply, BMI, age, gender, smoking status, genetic factors, impaired fasting glucose, and DM.^{4,12,17-19} Additionally, a study has investigated the role of environmental and lifestyle factors.⁶ In a few recent studies, thyroid cancer risk factors including iodine deficiency, environmental, genetic, family history of DM and hypertension, and lifestyle factors.^{6,8,10,13,17,20} The current study is confirmative with the documented literature determining the association between metabolic disorders characterized by insulin resistance and the risk of thyroid cancer with the underlying results.^{8,17,20} More recently, a few studies^{4,8,21} which have assessed how thyroid functions related to MetS prevalence in large

populations have revealed strong correlations between thyroid, and obesity, T2DM, and MetS. These results are confirmative with the current study.

Limitations and Strength of Study

Our study has several strengths but also some weaknesses. Firstly, the sample might be partially biased due to the retrospective cohort study. Secondly, we did not have data on the frequency of thyroid examinations in our study population. Thirdly, there was no cytological or histological results for each nodule. The greatest strengths of this study are the very large sample of participants and the large data set of risk factor variables such as TSH, T3, T4, body weight, physical activity, smoking cigarette, diet, BMI, family history of diabetes, hypertension, and thyroid.

Conclusion

The results of the current study confirm a strong positive association between MetS and thyroid nodules risk among patients with MetS. This study suggest that the patients with MetS can be considered as a marker to have moderately increased risk of future thyroid nodules and cancer. Meanwhile, MetS, obesity, and hyperglycemia could be a qualifiable and modifiable risk factor for thyroid nodules. The regularly glycemic control may be the most important treatment for the reduction in the incidence or prevention of thyroid. Therefore, it may lead to improve the quality of life in patients.

Authors' Note

A.B., M.Ö., and Y.Ö. designed and supervised the study and were involved in data collection, statistical analysis, and the writing of the paper. C.C.B. was involved in data collection, interpretation of data, and writing the manuscript. All authors approved the final version.

Acknowledgments

The authors would like to thank the Istanbul Medipol University for their support and ethical approval (Research Protocol and IRB# 10840098-604.01.01-E.8421).

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Istanbul Medipol University, International School of Medicine.

References

1. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis

- Society; and International Association for the Study of obesity. *Circulation*. 2009;120(16):1640-1645.
2. Bener A, Ziric M, Musallam M, Khader YS, Al-Hamaq AO. Prevalence of metabolic syndrome according to ATP III and IDF criteria: a population based study. *Metab Syndr Relat Disord*. 2009;7(3):221-230.
 3. Bener A, Al-Hamaq AO, Kurtuluş ME, Abdullatef WK, Ziric M. The role of vitamin D, obesity and physical exercise in regulation of glycemia in Type 2 Diabetes Mellitus patients. *Diabetes Metab Syndr*. 2016;10(4):198-204. doi:10.1016/j.dsx.2016.06.007
 4. Shin J, Kim MH, Yoon KH, Kang MI, Cha BY, Lim DJ. Relationship between metabolic syndrome and thyroid nodules in healthy Koreans. *Korean J Intern Med*. 2016;31(1):98-105.
 5. Blanc E, Ponce C, Brodschi D, et al. Association between worse metabolic control and increased thyroid volume and nodular disease in elderly adults with metabolic syndrome. *Metab Syndr Relat Disord*. 2015;13(5):221-226.
 6. Malaguarnera R, Vella V, Nicolosi ML, Belfiore A. Insulin resistance: any role in the changing epidemiology of thyroid cancer? *Front Endocrinol (Lausanne)*. 2017;8:314.
 7. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. *Cancer Epidemiol Biomarkers Prev*. 2009;18(3):784-791.
 8. Wolffenbuttel BHR, Wouters HJCM, Slagter SN, et al. Thyroid function and metabolic syndrome in the population-based Life Lines cohort study. *BMC Endocr Disord*. 2017;17(1):65.
 9. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. *Diabetes Care*. 2007;30(1):8-13.
 10. Wang K, Yang Y, Wu Y, et al. The association between insulin resistance and vascularization of thyroid nodules. *J Clin Endocrinol Metab*. 2015;100(1):184-192.
 11. Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. *Eur J Cancer*. 2008;44(2):293-297.
 12. Ayturk S, GURSOY A, Kut A, Anil C, Nar A, Tutuncu NB. Metabolic syndrome and its components are associated with increased thyroid volume and nodule prevalence in a mild-to-moderate iodine-deficient area. *Eur J Endocrinol*. 2009;161(4):599-605.
 13. Park HT, Cho GJ, Ahn KH, et al. Thyroid stimulating hormone is associated with metabolic syndrome in euthyroid postmenopausal women. *Maturitas*. 2009;62(3):301-305.
 14. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. *Circulation*. 2002;106(25):3143-3421.
 15. Brunn J, Block U, Ruf G, Bos I, Kunze WP, Scriba PC. Volumetric analysis of thyroid lobes by real-time ultrasound. *Dtsch Med Wochenschr*. 1981;106(41):1338-1340.
 16. Erdogan G, Erdogan MF, Emral R, et al. Iodine status and goiter prevalence in Turkey before mandatory iodization. *J Endocrinol Invest*. 2002;25(3):224-228.
 17. Duran AO, Anil C, GURSOY A, et al. Thyroid volume in patients with glucose metabolism disorders. *Arq Bras Endocrinol Metabol*. 2014;58(8):824-827
 18. Sari R, Balci MK, Altunbas H, Karayalcin U. The effect of body weight and weight loss on thyroid volume and function in obese women. *Clin Endocrinol (Oxf)*. 2003;59(2):258-262.
 19. Rezzonico J, Rezzonico M, Pusiol E, Pitoia F, Niepomniszcze H. Introducing the thyroid gland as another victim of the insulin resistance syndrome. *Thyroid*. 2008;18(4):461-464.
 20. Kir S, Aydin Y, Coskun H. Relationship between metabolic syndrome and nodular thyroid diseases. *Scand J Clin Lab Invest*. 2018;78(1-2):6-10.
 21. Kim JY, Kim KR. Dietary iodine intake and urinary iodine excretion in patients with thyroid diseases. *Yonsei Med J*. 2000;41(1):22-28.

Author Biographies

Abdulbari Bener is a professor of Public Health at the Cerrahpaşa Faculty of Medicine, Istanbul University and Istanbul Medipol University, International School of Medicine. He was a professor of Public Health in the Department of Public Health at the Weill Cornell Medical College for a period January 2006- August 2014. Professor Bener was an assistant medical director and the head of the Medical Statistics & Epidemiology Department at Hamad Medical Corporation, Qatar during August 2002- July 2014. Add to this, he is an advisor to World Health Organization and an adjunct professor & coordinator for the Postgraduate and Master public health programs (MPH) of the School of Epidemiology and Health Sciences, University of Manchester. He has been an author or co-author of more than 550 published journal articles. He is acting as an editor, associate editor, advisor editor and assistant editor for over 20 Journals and as a referee for over 60 Journals. He has contributed to more than 19 book chapters and supervised theses of 50 postgraduate students (MSc, MPH, MPhil and PhD).

Yaşar Özdenkaya graduated from the Istanbul Medical Faculty in 1997. He is working as an associate professor in the Department of General Surgery at the İstanbul Medipol University, İstanbul. He has been conducting research on the surgery of autism, robotic, thyroid, parathyroid and adrenal gland diseases. He conducts Laparoscopic Hernia Repair Course. He has publications and works on Comparison of Endoscopic and Robotic Thyroidectomy.

Cem Cahit Barışık graduated from the Istanbul Medical Faculty in 1989. Medical specialization postgraduate study was done in Haydarpaşa Numune Training and Research Hospital. Currently, Dr Cem is working as an associate professor and the Chief in the Departments of Radiodiagnostic and Pathology at the Istanbul Medipol University.

Mustafa Öztürk graduated from Faculty of Medicine, Hacettepe University in 1997. In 2001, he completed his specialty training at the Faculty of Medicine of Fatih University and became an internal medicine specialist. He specialized in the branch of metabolic syndrome, endocrinology, worked for many years at the Faculty of Medicine Van Yüzüncü Yıl University. Professor Öztürk is still an academic member of Faculty of Medicine at the Istanbul Medipol University .